Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Aug 1;54(4):389–393. doi: 10.1097/QAI.0b013e3181c42ea4

Figure 1.

Figure 1

Incomplete viral suppression on an integrase inhibitor based regimen is associated with continued viral evolution, as defined by the number of primary and secondary integrase mutations present at each consecutive visit (Panel A) and by the level of phenotypic resistance (Panel B). All subjects who had incomplete viral suppression and who remained on an integrase inhibitor-based regimen and who had interpretable genotypic resistance data are shown in Panel A (n=23, 25, 20 and 13 at baseline and visits 1–3, respectfully). All subjects who eventually developed evidence of integrase resistance are shown in Panel B (n=11).